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It has been proposed that the cytokine interleukin-lp (IL-IS), secreted by islet-infiltrating macrophages, may be involved in the pathogcnesis of
insulin-dependent diabetes mellitus by participation in /?-cell destruction. Addition of IL-IS to isolated pancreatic islets in vitro results in cytotoxic 
effects on &cell function, but there is little information on the intracellular events that convey the actions of the cytokine. In the present study, 
fetal rat pancreatic islets containing a high fraction of@cells were exposed in culture to IL-l& It was found that IL-l/? markedly decreased B-cell 
DNA synthesis, insulin secretion and cyclic AMP content. In order to explore whether the decrease inCAMP resulted from IL-l/l interaction with 
GTP-binding proteins coupled to adenylyl cyclase, islets were treated for 24 h with pertussis toxin prior to addition of cytokinc. While this treatment 
restored the decrease inCAMP, the reduced DNA synthesis and insulin secretion persisted. Pertussis toxin treatment without he addition of IL-@ 
resulted in increases in CAMP, DNA synthesis and insulin secretion. Addition of the stimulatory CAMP analog Sp-cAMPS also increased DNA 
synthesis and insulin secretion, but failed to affect the decrease in these functions evoked by IL-Q!?. The protease inhibitor Ncr-p-tosyl-L-lysinc 
chloromethyl ketone, recently shown to protect completely against IL-l/?-induced suppression of insulin production and secretion, was found to 
markedly reduce DNA synthesis without affecting insulin secretion. When the protease inhibitor was combined with IL-ID, the suppressed secretion 
was counteracted while DNA synthesis inhibition was not. It is concluded that CAMP stimulates DNA synthesis and insulin secretion in &cells, 
but that the inhibitory effect of IL-lp on these functions cannot be ascrilzed to the decrease inCAMP evoked by the cytokine. However, the repressive 
effect of the cytokine on insulin secretion, but not DNA synthesis, may be prevented by protcase inhibition. 
Cytokine; Pancreatic islet; DNA synthesis; Insulin secretion; Cyclic AMP; Protease 
1. INTRODUCTION 
Recent findings have shown that certain cytokines are 
able to exert both inhibitory and cytotoxic actions on 
pancreatic islet cells in vitro [l-8]. Cytokines are also 
known to be secreted by leukocytes infiltrating the islets 
early in the development of insulin-dependent diabetes 
mellitus [8]. These combined findings gave rise to the 
important notion that cytokines may be involved in the 
pathogenesis of this disease [5-81. The most extensively 
studied cytokine in this context, IL-l& inhibits insulin 
secretion at least in part by selectively interfering with 
mitochondrial substrate oxidation, leading to a reduced 
ATP-production [9]. One way by which the striking loss 
of B-cells, occurring during the development of insulin- 
dependent diabetes mellitus, can be compensated for, is 
via de novo formation of P-cells by replication. In the 
present study we have investigated the impact of IL-ID 
on DNA synthesis by cultured fetal pancrlztic islets 
containing a high fraction of/3-cells. In addition, il:e 
long-term influence of the cytokine also on regulation 
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of islet insulin secretion was evaluated. Attempts were 
also made to elucidate whether IL-1B affects the &!.ell 
by interaction with different parts of the CAMP signall- 
ing system or through protease activation. 
2. MATERIALS AND METHODS 
2.1. Materials 
Pertussis toxin and TLCK were from Sigma, St. Louis, MO. The 
Sp-diastereomer of cyclic adenosine-3’S’-monophosphothioate (Sp 
CAMPS) was delivered by Biolog Life Science Institute, Bremen, Ger- 
many. [methyl-‘H]Thymidine (5 Ci/mmol) and the CAMP assay kit 
(Cat.. no. RPA.509) were purchased from Amersham International, 
UK. Recombinant human IL-l/? was kindly provided by Dr Klaus 
Bend&en, Laboratory of Medical Immunology, Rigshospitalet, Uni- 
versity Hospital, Copenhagen, Denmark. The biological activity of the 
IL-IS was 5 U/pg, as determined by comparison with an interim 
international standard IL-ID preparation (NIBSC, London, UK) in 
the mouse thymocyte co-stimulatory assay and the EL4 murine T-cell 
line [IO]. The endotoxin content after adding the interleukin was ~1 
pB/ml. as measured in the Litnulus amoebocyte assay. We have 
previously found that neither 1 pglml nor 10 p&ml of endotoxin 
affected the growth or viability of insulin-producing cells [1 I]. 
2.2. Methods 
Pregnant Sprague-Dawley rats belonging to a local stock were 
killed by cervical dislocation on day 21 of gestation and the fetuses 
rapidly removed. Fetal rat islets were prepared from pancreatic glands 
as previously described [12-141. At the end of a S-day culture period 
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in medium RPM1 1640, groups of 50 islets were transferred to fresh 
media containing 1% fetal calf serum, with or without IL-IS or other 
test substances and cultured free-floating for 24 h. When pertussis 
toxin was included, islets were exposed to the toxin 24 h prior to IL-I/T 
addition in order to ensure that the effects of the toxin were expressed. 
The methods for analyzing islet cell DNA synthesis [ 13,141, DNA 
content [I 5,161 and insulin secretion [17] have ban published previ- 
ously. 
For CAMP measurements. cultured islets in groups of 50 were 
quickly washed in PBS and then transferred to tubes containing 150 
~1 6% trichloroacetic acid. These were immediately sealed, plunged 
into liquid nitrogen and stored at -80°C. pending anaiysis. The sam- 
ples were thawed by sonication on ice and centrifuged at 2000 x g 
(4OC) for 15 min. The pellet was re-sonicated in 200 ~1 of redistilled 
water and used for measurements of DNA and [‘Hlthymidine incorpo- 
ration as described above. The supematant was washed 4 times with 
5 vols of water-saturated diethyl ether. The aqueous extract was 
freeze-dried and the content of CAMP measured by RIA (using 
[‘*‘I]cAMP) exactly as described by the manufacturer of the assay kit. 
In order to increase the sensitivity of the method, samples were acety- 
lated. 
3. RESULTS 
Exposure of fetal rat islets to 25 U/ml of IL-IS for 24 
h resulted in a marked suppression of DNA synthesis, 
as assessed by measurements of [3H]thymidine incorpo- 
ration into DNA (Table I). IL-l/? also significantly in- 
hibited secretion of insulin from these islets over the 
24-h exposure period and lowered their content of 
CAMP by some 50% (Table I). Addition of pertussis 
toxin (50 @ml) in the absence of cytokine resulted in 
an increased CAMP content and a marked stimulation 
of DNA synthesis and insulin secretion (Table I). A 
24-h pertussis toxin pretreatment period was, however, 
not able to reverse the inhibition of DNA synthesis and 
insulin secretion evoked by IL-l/X despite a normaliza- 
tion of the CAMP content of these islets. Addition of the 
membrane-permeant stimulatory CAMP analog Sp- 
CAMPS (50 AM) also substantially enhanced DNA syn- 
thesis and insulin secretion rates (Table I), again effects 
that completely vanished in the presence of IL-l/3 (Table 
I). There were, however, no corresponding changes in 
islet DNA content in any of the groups (not shown), 
averaging 15 & 2 ng/islet, a finding which is not surpris- 
ing when considering that less than 10% of the fetal islet 
cells traverse through the cell cycle [18]. 
Treatment of islets for 24 h with the serine protease 
inhibitor TLCK (100 PM) inhibited islet cell DNA syn- 
thesis by approximately 75%, while leaving insulin 
secretion unaffected (Table II). TLCM also did not in- 
fluence the islet contents of insulin or DNA (not 
shown). When the protease inhibitor was combined 
with IL-la, the inhibited [3H]ahyrnidine incorporation 
::te persisted, whiIe there was a complete protection 
against the reduction of insulin secretion evoked by the 
cytokine (Table II). 
4. DISCUSSION 
The present study shows that the cytokine IL-lb ex- 
erts inhibitory actions not only on insulin secretion, but 
also on the proliferation, of fetal rat pancreatic islet cells 
in vitro. This cytokine is known to be produced by 
macrophages, which invade the pancreatic islets early in 
the course of insulin-dependent diabetes mellitus [5,7,8]. 
In addition, elevated serum levels of IL-1 in diabetic 
patients were recently noted [19]. It is therefore quite 
possible that this cytokine plays a key role in the devel- 
opment of insulin-dependent diabetes. There is little in- 
formation on the influence of cytokines on p-cell 
replication, in spite of the fact that de novo formation 
of j-cells by replication may be an important way to 
compensate for the loss of j&cells occurring in insulin- 
dependent diabetes. Nevertheless, it has been shown 
that IL-lfi decreases DNA synthesis in adult islet cells 
of rats 1201 and mice [21]. However, since adult islets 
contain only 70-80% j&ells, it cannot be excluded that 
these results reflect effects on non-&cells. 
In other cell types, IL-l/3 has been shown to activate 
intracellular proteases [22]. Recent evidence also in /$ 
cells suggests that a primary event in IL-lp action might 
Table 1 
Long-term effects of IL-Is, pertussis toxin and Sp-CAMPS on islet DNA synthesis. insulin secretion and CAMP content 
Islet culture DNA synthesis Insulin secretion CAMP content __ 
(cpm&g DNA) (ndpg DNA per ml x 24 h) (fmol/pg DNA) 
IL-ID PTX &-CAMPS 
1510 t 176 211 +29 107 ?r I2 
- + - 3055 + 293* 446 + 59* 161 2 21* 
+ 2891 t 320’ 399 r 44* N.D. 
+ - - 485 + 37, 92 + 20* 48 !Z lO* 
+ + 511 t 57*,+ II3 t l6*.+ 97 -(: 8#t 
+ + 458 + 72+.“ 106 + 13’” N.D. 
Groups of 50 fetal rat islets were cultured free-floating for 24 h in medium RPM1 1640 containing 1% fetal calf serum and supplemented with (+) 
or without (-) IL-IS (25 U/ml), pertussis toxin (PTX) or Sp-CAMPS (5OpM). When PTX was included, islets were treated with the toxin (50 n&ml) 
24 h prior to and during the entire IL-ID exposure period. Values are means + SEM for 4-8 experiments. *(vs. control islets). ‘(vs. IL-I@treated 
islets), ~(VS Sp-CAMPS-treated islets) and ‘(VS. PTX-treated islets) denote 95% multicomparison significance level using one-way factorial 
ANOVA. 
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be protease activation, since a complete protection 
against IL-I/J inhibition of insulin production and 
secretion in adult rat islets can be afforded by certain 
protease inhibitors [23]. The presently observed protec- 
tive effect of the serine proteasc inhibitor Ncl-p-tosyl-L- 
lysine chloromethyl ketone (TLCK) on the impairment 
of long-term insulin secretion evoked by IL-l@ fits 
nicely with these data. The tosyl-lysine group of TLCK 
forms a complex with enzymes recognizing basic and 
hydrophobic amino acid residues, whereas the chloro- 
methyl ketone group accounts for irreversible inactiva- 
tion of the enzyme by alkylating a catalytically active 
histidine [24]. Importantly, IL-IS itself is not affected by 
TLCK [23]. The unexpected finding of a potent growth 
inhibitory action of this protease inhibitor, makes it 
clear that the drug certainly cannot be used to coun- 
teract the repressive influence of IL-l/J on P-cell DNA 
synthesis. The mechanism by which TLCK inhibits 
DNA synthesis might be through its inhibition of tyro- 
sine kinases [25], enzymes that are believed to be instru- 
mental in the transduction of mitogenic signals by many 
growth factors. 
The presently reported reduction in the content of 
cyclic AMP in IL-l/3-treated islets might be suspected 
to contribute to the inhibitory actions of the cytokine 
on insulin secretion and DNA synthesis, since both pro- 
cesses reportedly are stimulated by cyclic AMP [2627]. 
One way by which a decrease in cyclic AMP can be 
brought about is through interference with GTP-bind- 
ing proteins that connect a cell surface receptor to ade- 
nylyl cyclase [28]. Certain of these inhibitory GTP-bind- 
ing proteins are sensitive to the toxin of Borderella per- 
fussis, which alleviates the adenylyl cyclase from an 
inhibitory constraint [28]. However, our present find- 
ings of a lack of protection by pertussis toxin pretreat- 
Table II 
Long-term effects of IL-l/l and TLCK on islet DNA synthesis and 
insulin secretion 
Islet culture DNA synthesis Insulin secretion 
(cpm&g DNA) (ng/,q DNA per ml x 24 h) 
Cnntrol 1093 & 139 123 + 16 
IL-IS (25 U/ml) 401 + 51* 61 f.8* 
TLCK (100 PM) 271 Z? 33* 139 t I9 
IL-IS + TLCK 243 + 2l*# 133 + l6# 
Groups of 50 fetal rat islets were cultured free-floating for 24 h in 
medium RPMI 1640 containing I % fetal calf serum and supplemented 
as indicated in the Table. During the final 5 h of culture, I &iiml 
[‘Hlthymidine was present in the culture medium and DNA synthesis 
rates were determined by measuring the radioactivity incorporated 
into trichloroacetic acid-prccipitablc material. The secretion ofinsulin 
into the culture medium during the 24 h of culture was determined 
radioimmunologically. Values are expressed as means t SEM for 6 
experiments. *(vs. controls) and *(vs. IL-la-treated islets) denote 95% 
multicomparison signifcancc level usiag one-way factorial ANOVA. 
ment despite a prevention of the decrease in CAMP 
suggest hat IL-l/J does not convey its inhibitory actions 
primarily by interfering with this pathway. Moreover, 
addition of the CAMP analog Sp-CAMPS was found to 
increasep-cell DNA synthesis and insulin secretion, but 
failed to affect the inhibitory action of IL-l/J on these 
parameters. These findings indicate that the decrease in 
CAMP elicited by IL- l/3 treatment is not responsible for 
the inhibition of DNA synthesis or insulin secretion 
evoked by the cytokine. Sp-CAMPS is a stimulatory 
analog of the natural signal molecule CAMP in which 
one of the two exocyclic oxygen atoms in the cyclic 
phosphate moiety is replaced by sulfur by axial modifi- 
cation. It mimics all biological effects of natural CAMP, 
is extremely resistant to cyclic nucleotide phosphodies 
terases and is an agonist of CAMP-dependent protein 
kinases I and II [29-321. The use of the membrane- 
permeant Sp-CAMPS makes it possible to avoid unde- 
sired side-effects of other CAMP analogs; e.g. stimula- 
tion of adenosine receptors by 8-bromo CAMP or ‘buty- 
rate effects’ by dibutyryl CAMP. We have found that 
butyrate itself inhibits islet DNA synthesis and comple- 
tely blocks the mitogenicity of the adenylyl cyclase acti- 
vator forskolin (AS., unpublished). Thus, the true role 
of CAMP in B-cell replication may be severnly obscured 
by using dibutyryl CAMP, a problem that can be 
avoided by using Sp- CAMPS. 
It is concluded that long-term IL-l/l exposure inhibits 
both the proliferation and insulin secretion by fetal p- 
cells. Our results furthermore indicate that CAMP stim- 
ulates DNA synthesis and insulin secretion in &zells, 
but that the inhibitory effect of IL-lfl on these functions 
cannot be ascribed to the decrease in CAMP evoked by 
the cytokine. However, the repressive effect of IL-l/3 on 
insulin secretion, but not DNA synthesis, may be coun- 
teracted by protease inhibition. These direct effects of 
IJ_,-lp on the insulin-secreting cells may prove valuable 
for the understanding of the putative role of cytokines 
in the development of insulin-dependent diabetes mel- 
litus. 
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